Planned Treatment Interruptions and Chemotherapy-Free Intervals in the Treatment of Metastatic Colorectal Cancer: Time to Start Stopping?

Seminars in Oncology

Volumn 33, Issue SUPPL. 11, 2006, Pages 28-32

  Saltz, Leonard ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; BEVACIZUMAB; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DIARRHEA; DISEASE FREE INTERVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FATIGUE; HEALTH CARE COST; HUMAN; LONG TERM CARE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; TIME FACTORS;

EID: 33845425012     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.10.009     Document Type: Article

References (8)

1. Green E, Sargent DJ, Goldberg RM, et al: Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. Presented at 2005 ASCO Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to Gastrointestinal Malignancies and Premalignancies, January 27-29, 2005, Hollywood, FL. (abstr 182). Available at: http://www.asco.org
2. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: A GERCOR study. J Clin Oncol 24 (2006) 394-400
3. Maindrault-Goebel F., Lledo G., Chibaudel B., et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 24 suppl (2006) 3504A (abstr)
4. Labianca R., Floriani I., Cortesi E., et al. Alternating versus continuous FOLFIRI in advanced colorectal cancer (ACC): A randomized GISCAD trial. J Clin Oncol 24 suppl (2006) 3505A (abstr)
5. Tournigand C., Perez N., Buyse M., et al. OPTIMOX study: Influence of reintroduction rate on survival. Ann Oncol 15 suppl 3 (2004) 344P (abstr)
6. Lal R., Dickson J., Cunningham D., et al. A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 22 (2004) 3023-3031
7. Chen H.X., Mooney M., Boron M., et al. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). J Clin Oncol 22 suppl (2006) 3515A (abstr)
8. Giantonio B.J., Catalano P.I., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23 suppl (2005) 2A (abstr)